NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate...
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition...
Third-Quarter 2025 and Recent Selected Highlights:Â Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted...
NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...
In a report released today, Chase Knickerbocker from Craig-Hallum reiterated a Buy rating on Harrow Health, with a price target of $64.00. The company’s shares closed last Friday at $37.48.Elevate Your...
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Harrow Health. The company’s shares closed last Friday at $45.43.Elevate Your Investing Strategy: Take advantage...
In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on Harrow Health, with a price target of $70.00. The company’s shares closed last Friday at $45.43.Elevate Your Investing...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Harrow Health...
Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW),...